Cardiovascular Pharmacology: Open Access

Alexander E. Berezin

Publications

• Mini Review
  The Metabolic Effects of Mineralocorticoid Receptor Antagonists in Heart Failure Patients
  Author(s): Alexander E. Berezin Alexander E. Berezin
  
  Heart failure (HF) remains a leading cause of cardiovascular morbidity and mortality worldwide. Mineralocorticod receptor (MR) antagonists (spironolactone and eplerenone) have been studied in HF patients and in patients with acute coronary syndrome or post-myocardial infarction and left ventricular (LV) dysfunction, as well as hypertensive subjects without HF symptoms. It has suggested that mineralocorticoid receptor antagonists provide cardiovascular protection beyond its diuretic and potassium-sparing capacities. Traditionally, progression of HF relates with not full blockade of renin-angiotensin system (RAS) activation and with so called “escape” phenomenon of neurohumoral activation from effects of angiotensin converting enzyme / angiotensin receptor blockers and beta-adrenoblockers. Circulating and local aldosteron over production is discussed a main cause of none ade.. View More»
  DOI: 10.4172/2329-6607.1000145

  Abstract PDF